All Outputs (2)

A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up (2012)
Journal Article
Johnston, S. J., Kenny, F. S., Syed, B. M., Robertson, J. F. R., Pinder, S. E., Winterbottom, L., …Cheung, K. L. (2012). A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up. Annals of Oncology, 23(9), 2296-2300. https://doi.org/10.1093/annonc/mdr630

Background Long-term analysis of a randomised trial in Nottingham comparing tamoxifen versus surgery as initial treatment demonstrated that in oestrogen receptor (ER)-unselected cases, surgery achieved better local control, with no difference in ove... Read More about A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up.

The prognostic and predictive power of redox rotein expression for anthracycline-based chemotherapy response in locally advanced breast cancer (2012)
Journal Article
Woolston, C. M., Zhang, L., Storr, S. J., Al-Attar, A., Shehata, M., Ellis, I. O., …Martin, S. G. (in press). The prognostic and predictive power of redox rotein expression for anthracycline-based chemotherapy response in locally advanced breast cancer. Modern Pathology, 25, https://doi.org/10.1038/modpathol.2012.60

Neoadjuvant chemotherapy has become the standard of care for locally advanced primary breast cancer. Anthracycline-based regimens have proven to be one of the most effective treatments in this setting. As certain cytotoxic antineoplastic agents, such... Read More about The prognostic and predictive power of redox rotein expression for anthracycline-based chemotherapy response in locally advanced breast cancer.